ARCHIVES

Cancer Groups Urge FDA To Spell Out Standards For Data Collection In Time-To-Progression Trials.

This article is from The Cancer Letter archive.

Vol. 34 No. 41 | November 7, 2008

Download PDF Visit The Full Archive

Related Articles

ODAC Meets at ASCO, Recommends Approval Of Dasatinib For CML.

June 9, 2006

Health Professional Training Needs Improvement, IOM Says.

July 4, 2003

Includes Sept. Business & Regulatory Report.

September 26, 2003

New Model Provides Better Estimate of Breast Cancer Risk in Black Women.

November 30, 2007

Gerstner Resigns From NA, MSK Board After Taking RJR Job

March 24, 1989

Improved NCI Relations With FDA Cited As Model For Government Accord, Lasagna Committee Says

April 20, 1990